Cetuximab + Taxotere With Low Dose Fractionated Radiation for Head and Neck Carcinoma

The investigator's approach is based on the following reasons: * Low dose hyper-radiation sensitivity response will be significantly enhanced in Taxotere- induced G2/M cell cycle arrest. * LDFRT will render enhanced bax activation mediated mode of cell death. * Erbitux will arrest the cells in G1/G0 phase leading to p21-mediated mode of cell death. * The toxicity profile is expected to be minimal. Based on the above mentioned reasons, we propose this novel schema of treatment in recurrent SCCHN.